» Authors » Jose Luis Poveda

Jose Luis Poveda

Explore the profile of Jose Luis Poveda including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 359
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Diego D, Badia X, Benitez-Hidalgo O, Jimenez V, Juarez J, Nunez R, et al.
Haemophilia . 2024 Sep; 30(6):1281-1287. PMID: 39340327
Introduction: The value of gene therapies for haemophilia needs to be assessed holistically. Aim: To determine the value of etranacogene dezaparvovec (ED) compared to current extended half-life (EHL) recombinant factors...
2.
Badia X, Calleja M, Escudero-Vilaplana V, Perez-Martinez A, Pinana J, Poveda J, et al.
Orphanet J Rare Dis . 2024 Aug; 19(1):308. PMID: 39180132
Background: The aim of this study was to assess the contribution of the reflective multidisciplinary discussion in determining the value contribution of innovative drugs through the multi-criteria decision analysis (MCDA)....
3.
Abad M, Alerany C, Alsina L, Lopez Granados E, Neth O, Poveda J, et al.
Glob Reg Health Technol Assess . 2024 May; 11:124-130. PMID: 38784663
Introduction: Activated phosphoinositide 3-kinase (PI3K)δ syndrome (APDS) is an ultra-rare inborn error of immunity (IEI) combining immunodeficiency and immune dysregulation. This study determined what represents value in APDS in Spain...
4.
Plaza J, Minguez A, Bastida G, Marques R, Nos P, Poveda J, et al.
Int J Mol Sci . 2024 Apr; 25(7). PMID: 38612528
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the digestive tract usually characterized by diarrhea, rectal bleeding, and abdominal pain. IBD includes Crohn's disease and ulcerative colitis as...
5.
Pozo-Rosich P, Poveda J, Crespo C, Martinez M, Rodriguez J, Irimia P
J Headache Pain . 2024 Mar; 25(1):40. PMID: 38491460
Background: The reimbursement of erenumab in Spain and other European countries is currently restricted because of the cost of this novel therapy to patients with migraine who have experienced previous...
6.
Bonanad S, Alvarez M, Nunez R, Poveda J, Gil B, Ruiz-Beato E, et al.
Glob Reg Health Technol Assess . 2023 Jan; 8:35-42. PMID: 36627877
Introduction: Emicizumab is a first-in-class monoclonal antibody, recently authorized for the treatment of hemophilia A with inhibitors. This study aims to estimate the direct and indirect costs of the management...
7.
Poveda J, Gomez C, Gil A, Badia X
Orphanet J Rare Dis . 2023 Jan; 18(1):4. PMID: 36609401
Background: The present study aims to assess clinical and regulatory variables that would influence pricing and reimbursement (P&R) decisions for Orphan Drugs (ODs) in Spain. ODs approved by the European...
8.
Poveda J, Breton-Romero R, Del Rio-Bermudez C, Taberna M, Medrano I
J Pharm Policy Pract . 2022 Nov; 15(1):85. PMID: 36401303
Efforts in the pharmaceutical market have been aimed at ensuring that the benefits obtained from the introduction of new therapies justify the associated costs. In recent years, drug payment models...
9.
Gil-Nagel A, Falip M, Sanchez-Carpintero R, Abad-Sazatornil M, Poveda J, Aibar J, et al.
Epilepsy Behav . 2022 May; 132:108711. PMID: 35588562
Introduction: Dravet Syndrome (DS) is a severe, developmental epileptic encephalopathy (DEE) that begins in infancy and is characterized by pharmaco-resistant epilepsy and neurodevelopmental delay. Despite available antiseizure medications (ASMs), there...
10.
Megias-Vericat J, Martinez-Cuadron D, Solana-Altabella A, Poveda J, Montesinos P
Pharmaceutics . 2022 Apr; 14(4). PMID: 35456712
Antineoplastic uptake by blast cells in acute myeloid leukemia (AML) could be influenced by influx and efflux transporters, especially solute carriers (SLCs) and ATP-binding cassette family (ABC) pumps. Genetic variability...